NEW YORK, June 9, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it was informed by the Defense Threat Reduction Agency (DTRA) that its Phase II proposal entitled “Therapeutic Countermeasures Against CDC Category A and B Threat Agents” has been selected for an award of funding. The award is subject to negotiation of a final contract with DTRA. DTRA informed SIGA that it expects contract signing and the beginning of funding to occur 90-120 days following initiation of negotiations. Viruses designated “Category A” and “Category B” by the U.S. Centers for Disease Control and Prevention (CDC) can generate high morbidity and mortality, and many of these viruses are endemic in areas where U.S. military personnel may be deployed.
